EMA Authorised: Ekterly (sebetralstat) — Kalvista Pharmaceuticals (Ireland) Limited

View source ↗

Summary

The EMA authorised Ekterly (sebetralstat) from Kalvista Pharmaceuticals for the treatment of hereditary angioedema, marking an approved therapy for this orphan …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• EKTERLY (SEBETRALSTAT)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: Kalvista Pharmaceuticals (Ireland) Limited. Decision date: 17/09/2025. Orphan medicine